Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Price Crosses Above 50-Day Moving Average – Here’s Why

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO)’s stock price passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $0.25 and traded as high as $0.2849. Northwest Biotherapeutics shares last traded at $0.2821, with a volume of 2,464,998 shares trading hands.

Northwest Biotherapeutics Price Performance

The firm has a market capitalization of $444.27 million, a price-to-earnings ratio of -0.02 and a beta of -0.86. The firm’s 50-day moving average price is $0.25 and its 200 day moving average price is $0.25.

Northwest Biotherapeutics (OTCMKTS:NWBO) last posted its earnings results on Friday, November 14th. The biotechnology company reported ($18.22) earnings per share (EPS) for the quarter. The company had revenue of $0.20 million for the quarter.

Northwest Biotherapeutics Company Profile

Northwest Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.

The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial.